RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2011 /PRNewswire/ -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) announced today that it has established a new record date and meeting date for the special meeting of shareholders to vote on the previously announced merger agreement under which Grifols (GRF.MC) will acquire TLCR.
TLCR shareholders of record at the close of business on January 11, 2011 will be entitled to vote at the special meeting. The TLCR board set the date for the special meeting of shareholders to be held at 3:30 p.m., local time, on February 14, 2011, at Research Triangle Park Marriott, located at 4700 Guardian Drive, Durham, North Carolina 27703. This date takes the place of the previously announced date of January 21, 2011.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com.
|SOURCE Talecris Biotherapeutics Holdings Corp.|
Copyright©2010 PR Newswire.
All rights reserved